AbbVie Inc.
ABBVHealthcareNASDAQDrug Manufacturers - General
Scan Results
Daily timeframeHeadquartered within the healthcare sector, AbbVie Inc. focuses on Drug Manufacturers - General services and products. AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company carries a $449.63B market cap, placing it firmly in the mega-cap category. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer.
Market Cap
$449.63B
Beta
0.28
P/E (TTM)
124.75
P/E (Fwd)
15.63
EPS (TTM)
$2.04
EPS (Fwd)
$16.28
ROE
—
ROA
10.0%
Cash
$9.39B
Total Debt
$72.91B
Free CF
$20.81B
52W Change
34.5%
Annual Financials
Cash vs Debt
The company holds $9.39B in cash, though total debt stands at $72.91B. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Annual free cash flow of $20.81B supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. Return on assets of 10.0% further supports the picture of efficient asset utilization. Revenue has been relatively flat, moving from $56.20B (2021) to $61.16B (2025).
The relatively low beta of 0.28 suggests ABBV is a less volatile holding compared to the broader index. AbbVie Inc. carries a heavier debt load relative to its cash position, which introduces financial risk that investors should weigh. At over 50x earnings, ABBV carries valuation risk — any slowdown in growth expectations could lead to meaningful price adjustments. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence AbbVie Inc.'s trajectory.